Myriad and Moderna and the furin cleavage site.
Working on index card files about the big picture of global geopolitics and theology opened to view by the Covid crisis.
I’ve used this technique a lot over the years as an investigator, mostly looking at municipal, county and corporate corruption in New Jersey and Pennsylvania up to this point.
I write the dates, names, authors, sources, and key points of key documents on individual index cards, so that I can sort them all chronologically and then pull out and look at card clusters about subtopics, and then put them all back together and write timelines and reports.
This sequence popped up today when I started intercalating a new batch into the set I started a couple of days ago.
2013/06/13 - US Supreme Court. Association for Molecular Pathology et al v. Myriad Genetics Inc. GMO organisms owned by patent-holders.
2013/12/16 - Moderna patent application, furin cleavage site. US9149506B2; US9216205B2; US9255129B2; US9301993B2. DailyExpose.uk report, 3/14/2022.
As reported — from Attorney Todd Callender’s Jan. 30, 2022 interview — in Legal Walls of the Covid-19 Kill Box:
The Myriad court found in favor of the biotech corporation and the federal government, ruling that naturally-occurring DNA is not patentable, but synthetic cDNA is patentable…
Between Chakrabarty in 1980 and Myriad in 2013, and since, several court cases involving Monsanto, Dupont, Syngenta and other biotech corporations developed an ownership and licensing paradigm for patented living organisms such as plant seeds and research animals…
The result: under international and American intellectual property and patent law, the act of genetic modification results in the modification-device patent holders owning the modified biological subject…
I originally interpreted Callender’s point from the Jan. 30, 2022 interview to mean that pharmaceutical corporations including Pfizer and Moderna could at some point — if the law is not changed and the Myriad precedent stands — make a claim to legal ownership of any living human being who has been injected with their pharmaceutical products (full contents unknown, negating any possibility of informed consent), to the extent the products have altered the genetic material of recipients by artificially inducing mRNA/DNA-mediated immune system responses.
My current understanding is that, since the Moderna-patented sequence coding for the furin cleavage site has been found in SARS-CoV-2 itself, Moderna could potentially make a claim to legal ownership of any living human being who has contracted and recovered from Covid-19, thus acquiring natural immunity, to the extent that SARS-CoV-2 infection alone results in genetic modification by stimulating mRNA/DNA-mediated innate immune system responses.
TIMELINE*
This hypothesis is supported by other documents in the timeline, including:
2013/06/13 - US Supreme Court. Association for Molecular Pathology et al v. Myriad Genetics Inc. GMO organisms owned by patent-holders.
2013/12/16 - Moderna patent application, furin cleavage site. US9149506B2; US9216205B2; US9255129B2; US9301993B2. DailyExpose.uk report, 3/14/2022.
2018/10/09 - Technologies to Address Global Catastrophic Biological Risks, Johns Hopkins Centre for Health Security, at p. 48: “self-spreading vaccines.”
Self-spreading vaccines—also known as transmissible or self-propagating vaccines—are genetically engineered to move through populations in the same way as
communicable diseases, but rather than causing disease, they confer protection. The vision is that a small number of individuals in the target population could be
vaccinated, and the vaccine strain would then circulate in the population much like a pathogenic virus. These vaccines could dramatically increase vaccine coverage in human or animal populations without requiring each individual to be inoculated.
2019/12/12 - Material transfer agreement from US-NIAID/NIH and Moderna to UNC Chapel Hill/Ralph Baric, mRNA coronavirus vaccine candidates developed and jointly owned by NIAID and Moderna.
2020/05/13 - An infectious cDNA clone of SARS-CoV-2, Xie et al, Cell Host & Microbe
We report a reverse genetic system for SARS-CoV-2. Seven complimentary DNA (cDNA) fragments spanning the SARS-CoV-2 genome were assembled into a full-genome cDNA. RNA transcribed from the full-genome cDNA was highly infectious after electroporation into cells, producing 2.9 x 10 >6 plaque-forming unit (PFU)/mL of virus. Compared with a clinical isolate, the infectious-clone-derived SARS- CoV-2 (icSARS-CoV-2) exhibited similar plaque morphology, viral RNA profile, and replication kinetics.
Our reverse genetic system represents a major reagent in the pursuit of understanding SARS-CoV-2 and COVID-19. Compared with the clinical isolate, the recombinant WT SARS-CoV-2 has no deficit in terms of viral RNA species produced, plaque morphology, or replication kinetics. Therefore, it might be used as an equivalent to the clinical strain, and mutant viruses can be generated to characterize mutational effect on viral infection. This approach has allowed researchers to identify key viral antagonists of innate immunity for SARS-CoV and MERS-CoV (Menachery et al., 2015; Totura and Baric, 2012). Several of these mutant viruses have subsequently been employed as live-attenuated vaccine candidates for SARS-CoV and MERS-CoV (de Wit et al., 2016; Schindewolf and Menachery, 2019). Using our system, this knowledge might now be applied to the current SARS-CoV-2.
2021/04/01 - Golden Silkworms in Pandora’s Box, Dan Sirotkin, summarizing this paper.
“SARS-CoV-2 is a circulating vaccine-derived-coronavirus (cVDCV) borne from work originally done at the University of North Carolina [Ralph Baric lab], the only institution on earth that’s been attempting to design a live-attenuated vaccine for SARS, where they also pioneered engineering the sort of SARS-like chimeric coronaviruses that would be needed as templates for attenuation, and did their best to ignore or circumvent restrictions on gain-of-function research – obfuscation that’s still ongoing as they refuse to disclose genomic details relating to lab accidents that occurred during the above publicly-funded research.”
2021/08/21 - Major Joseph Murphy’s report to Department of Defense Inspector General
SARS-CoV-2 is “a synthetic spike protein chimera engineered to attach to human ACE-2 receptors and inserted into a recombinant bat SARSr-CoV backbone.”
2021/11/17 - Revision to 42 CFR 73.3 by US Department of Health and Human Services:
"SARS-CoV/SARS-CoV-2 chimeric viruses resulting from any deliberate manipulation of SARS-CoV-2 to incorporate nucleic acids coding for SARS-CoV virulence factors" added to the list of "biological agents and toxins listed in this section [that] have the potential to pose a severe threat to public health and safety" in 42 CFR 73.3. See also 86 Federal Register 64081.
2022/02/21 - MSH3 Homology and Potential Recombinatant links to SARS-CoV-2 furin cleavage site, Ambati et al, Frontiers in Virology. [Although the authors mention Moderna’s 02/04/2016 patent application, they do not mention the four previous patent applications filed 12/16/2013. Those were located by the author of the DailyExpose.uk report, published 03/14/2022.]
A peculiar feature of the nucleotide sequence encoding the PRRA furin cleavage site in the SARS-CoV-2S protein is its two consecutive CGG codons. This arginine codon is rare in coronaviruses: relative synonymous codon usage (RSCU) of CGG in pangolin CoV is 0, in bat CoV 0.08, in SARS-CoV 0.19, in MERS-CoV 0.25, and in SARS-CoV-2 0.299 (9).
A BLAST search for the 12-nucleotide insertion led us to a 100% reverse match in a proprietary sequence (SEQ ID11652, nt 2751-2733) found in the US patent 9,587,003 filed on Feb. 4, 2016.
2022/02/25 - Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line, Alden et al, Current Issues in Molecular Biology.
In this study we present evidence that COVID-19 mRNA vaccine BNT162b2 is able to enter the human liver cell line Huh7 in vitro. BNT162b2 mRNA is reverse transcribed intracellularly into DNA as fast as 6 h after BNT162b2 exposure. A possible mechanism for reverse transcription is through endogenous reverse transcriptase LINE-1, and the nucleus protein distribution of LINE-1 is elevated by BNT162b2.
2022/03/14 - Whilst you were distracted by the Battle for Ukraine, documents were published confirming Moderna created the Covid-19 Virus. DailyExpose.uk
…I can confirm, and the reader can confirm using the links above, that Moderna did apply for a Patent not only on the reverse compliment of the 12 nucleotide Furin Cleavage Site in Covid-19 but actually on the 19 nucleotide sequence containing it as described above.
Furthermore they did not merely apply for a patent on 2016 February 4 with US9587003B2, as reported in the Daily Mail. They actually applied on 2013 December 16 for 4 patents with US9149506B2, US9216205B2, US9255129B2, US9301993B2, as well.
So Moderna had developed the 19 nucleotide gene sequence containing the Furin Cleavage Site which gives Covid19 its infectivity to humans by patented gain of function research as early as 2013, six years before the Wuhan outbreak took place. Not three as reported in the Mail and virally elsewhere…
*Update 3/16/22 at 9:30 p.m. - For a few hours today, I added some timeline points for papers and patents cited in Igor Chudov’s DNA posts published between 2/19/22 and 3/14/22, but I changed my mind and pulled them off this timeline because they’re not directly related to the furin cleavage site. Will leave this post static from here on, and work on building a master timeline instead.